Headquartered in California, Abide has developed a platform to discover potent and selective serine hydrolase inhibitors. The platform is used by the company to identify, develop, and validate
Pear Therapeutics is developing Pear-006 in collaboration with Novartis under the terms of an agreement announced in March 2018. Clinicians estimate that between 35-50% of people with MS
Innovative oncolytic viruses resulting from this collaboration will use Transgene’s proprietary next generation viral platform Invir.IO. Under the terms of the agreement Transgene will contribute its oncolytic virus
The primary endpoint of the trial is progression-free survival, and the secondary endpoints are overall survival and objective response rate. “Clinical observations suggest cabozantinib promotes an immune-permissive environment,
KALYDECO is already approved in the U.S., Canada and EU for the treatment of CF in patients ages 12 months and older. “Today’s approval for KALYDECO allows physicians
The collaboration will combine the genomics, chemistry and clinical data of AstraZeneca with the target identification platform and biomedical knowledge graph of BenevolentAI. BenevolentAI’s biomedical knowledge graph is
Under the collaboration, Iktos virtual drug design technology will be implemented and applied to various Janssen small molecule drug discovery programs. The French firm will collaborate with the
The CHMP’s recommendation is for the use of LYNPARZA as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or
Luspatercept is an erythroid maturation agent (EMA), which has been designed to regulate late-stage red blood cell maturation. The drug is being jointly developed by Acceleron and Celgene
Relevance of the Study The purpose of the study is to explore using 68Ga-Tilmanocept as an aid in TB patient management while contributing to the better understanding of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.